$3.50
2.19%
Nasdaq, Nov 19, 03:59 pm EST. Closed.
ISIN
US1856341029
Symbol
CLNN

Clene Inc Stock price

$3.50
+0.21 6.38% 1M
-2.88 45.14% 6M
-2.37 40.37% YTD
-5.15 59.54% 1Y
-5.92 62.85% 3Y
-97.50 96.53% 5Y
-189.50 98.19% 10Y
-189.50 98.19% 20Y
Nasdaq, Closing price Thu, Nov 19 2026
+0.08 2.34%
ISIN
US1856341029
Symbol
CLNN
Industry

Is Clene Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$49.3m
Enterprise Value
$58.3m
Net debt
$9.1m
Cash
$9.7m
Shares outstanding
12.8m
Valuation
P/E
negative
P/S | estimate
246.2 | 193.6
EV/Sales | estimate
291.5 | 229.2
EV/FCF | ex SBC
negative | negative
P/B
negative
Financial Health
Equity Ratio
-97.0%
Return on Equity
148.8%
ROCE
-113.0%
ROIC
-
Debt/Equity
-0.8
Share-Based Compensation & Dilution
SBC | % of Revenue
$5.4m | 2,710.0%
SBC as % of FCF
-
SBC Growth 1Y
-25.8%
Share Count Growth 1Y
35.1%
Shareholder Yield
-35.1%
Financials
Revenue | estimate
$200.0k | $254.4k
EBITDA
$-19.1m
EBIT
$-20.6m
Net Income
$-39.5m
Free Cash Flow | ex SBC
$-16.0m | $-21.4m
Growth
Revenue | estimate
-31.0% | 27.2%
EBITDA
23.6%
EBIT
22.8%
Net Income
-33.0%
Free Cash Flow
9.6%
Margin
Gross
70.1%
EBITDA
-9,704.6%
EBIT
-10,432.0%
Net
-20,059.9%
Free Cash Flow | ex SBC
-8,094.9% | -10,846.2%
More
EPS
$-3.2
FCF per Share
$-1.2
Short interest
3.8%
Employees
78
Rev per Employee
$0.0

Clene Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Clene Inc forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Clene Inc forecast:

Buy
91%
Hold
9%

Financial data from Clene Inc

Jun '26
+/-
%
0.20 0.20
31% 31%
100%
- Direct Costs 0.06 0.06
0% 0%
30%
0.14 0.14
39% 39%
70%
- Selling and Administrative Expenses 7.79 7.79
32% 32%
3,895%
- Research and Development Expense 20 20
44% 44%
9,840%
-19 -19
24% 24%
-9,560%
- Depreciation and Amortization 1.43 1.43
9% 9%
715%
EBIT (Operating Income) EBIT -21 -21
23% 23%
-10,276%
Net Profit -40 -40
33% 33%
-19,760%

In millions USD.

Don't miss a Thing! We will send you all news about Clene Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Clene Inc Stock News

Neutral
Business Wire
●
7 days ago
SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) f...
Neutral
GlobeNewsWire
●
16 days ago
SALT LAKE CITY, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced its third quarter 2026 financial results and provided updates on its CNM-Au8 programs.
Neutral
GlobeNewsWire
●
about one month ago
SALT LAKE CITY, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on revolutionizing the treatment of neurodegenerative diseases, announced that it has submitted a New Drug Application (NDA) earlier in October to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of CNM-Au8® for the treatment of amyotrophic lateral ...
More Clene Inc News

Company Profile

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Mr. Etherington
Employees 78
Founded 2013
Website clene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today